TABLE 1.
Characteristics of Patients Who Developed a Second Stomach Cancer and Matched Controls by First Cancera
| Registry | First cancera; total no. of patients
(cases/controls) |
|||
|---|---|---|---|---|
| Hodgkin lymphoma | Testicular cancer | Cervical cancer | Combined | |
| Total no. of patients (cases/controls) | 183 (48/135) | 260 (86/174) | 562 (193/369) | 1,005 (327/678) |
| No. of cases/controls (%b) | ||||
| Denmark | 2/6 (4.4) | 18/26 (16.9) | 50/79 (22.9) | 70/111 (18.0) |
| Finland | 7/13 (10.9) | 6/12 (6.9) | 42/90 (23.5) | 55/115 (16.9) |
| Iowa | 2/9 (6.0) | 0/0 (0.0) | 1/2 (0.5) | 3/11 (1.4) |
| Ontario | 13/28 (22.4) | 4/10 (5.4) | 19/38 (10.1) | 36/76 (11.1) |
| Sweden | 11/28 (21.3) | 19/40 (22.7) | 81/160 (42.9) | 111/228 (33.7) |
| Norway | 8/13 (11.5) | 18/36 (20.8) | Not included | 26/49 (7.5) |
| Netherlands | 5/38 (23.5) | 21/50 (27.3) | Not included | 26/88 (11.3) |
| Age at first cancer diagnosis (years) | ||||
| Mean | 36.2 | 39.4 | 53.7 | 46.8 |
| Median | 30.0 | 38.6 | 54.2 | 46.5 |
| Range | 12.2–83.7 | 18.3–71.8 | 26.3–83.0 | 12.2–83.7 |
| Time since first cancer diagnosis (years) | ||||
| Mean | 16.9 | 17.9 | 19.0 | 17.8 |
| Median | 15.8 | 17.2 | 16.8 | 16.8 |
| Range | 5.2–35.8 | 7.3–38.8 | 5.0–41.8 | 5.0–41.8 |
| Year of first cancer diagnosis | ||||
| Mean | 1974.3 | 1973.7 | 1966.5 | 1969.8 |
| Median | 1973 | 1973 | 1966 | 1970 |
| Range | 1953–1992 | 1959–1987 | 1943–1995 | 1943–1995 |
| Age at stomach cancer diagnosis or comparable date for controls (years) | ||||
| Mean | 53.1 | 57.3 | 71.6 | 64.5 |
| Median | 50.4 | 57.6 | 72.3 | 65.9 |
| Range | 25.8–89.1 | 31.5–80.3 | 35.7–97.5 | 25.8–97.5 |
| No. of cases/controls treated with external beam therapy (%b) | 46/128 (95.1) | 82/145 (87.3) | 165/300 (82.7)d | 293/573 (86.2) |
| No. of cases/controls treated with chemotherapy (%b) | 17/56 (39.9) | 14/23 (14.2) | 1/7 (1.4) | 32/86 (11.7) |
| Radiation dose to the stomach (tumor location for cases, matched location for controls) (Gyc) | ||||
| Mean | 15.3 | 24.7 | 1.9 | 10.3 |
| Median | 2.6 | 28.0 | 1.3 | 1.9 |
| Rangee | 0.08–49.0 | 0.39–59.1 | 0.12–45.8 | 0.08–59.1 |
Excludes 16 cases and 2 controls for whom radiation dose could not be estimated and 40 Hodgkin lymphoma cases and 48 Hodgkin lymphoma controls who received ≥5,600 mg/m2 of procarbazine (1 case and 2 controls were in both excluded groups).
Percentages are based on combined cases and controls.
Excludes 2 Hodgkin lymphoma patients and 6 cervical cancer patients who received radiation only in the five-year period preceding the stomach cancer diagnosis or comparable date for controls. None of these patients received doses >2 Gy in this time period.
An additional 24 cervical cancer cases and 45 cervical cancer controls received brachytherapy but no external beam therapy.
Excludes doses of zero.